With the start of 2021 Biomedycyna Polska S. A. group has begun a cooperative research and development project with the Ludwik Hirszfeld Institute of Immunology and Experimental Therapy of Polish Academy of Sciences in Wrocław (IITD – pol. Instytut Immunologii i Terapii Doświadczalnej).

Signed by prof. Andrzej Gamian, director of the Institute, the agreement is a result of intensified efforts coordinated by prof Michał Zimecki – head of the Laboratory of Immunology and the Department of Experimental Therapy. Future projects of interdisciplinary nature will be led by IITD and will include within their scope research and development of medicinal product TFX (Thymostimulinum) – an immunomodulator, one of the 7 original Polish medicinal products – with the goal of further the identifying the mechanisms of action and finding new therapeutic indications.

The cooperation is a continuation of earlier research coordinated by prof. Zimecki, which has proven therapeutic potential of TFX against neurodegenerative diseases, such as multiple sclerosis. It has been observed that intramuscular injection of a thymus extract fraction significantly reduced clinical, immunologic, histologic and ultrastructural changes characteristic for that disease.

IITD is conducting research in the fields of immunology, oncology, microbiology and experimental therapy and is also supporting developmental and implementational projects in cooperation with industrial partners as well as getting involved in initiatives that increase Polish scientific potential. The institute has been assigned category A in the Life Sciences group and has been designated a Leading National Research Centre (KNOW – pol. Krajowy Naukowy Ośrodek Wiodący).